CRISPR/Cas9 Genome-edited Drug-resistant Cell Models: An Advanced Approach for Overcoming Drug Resistance Webinar
April 14, 2022, at 12:00 PM ETAbstract
Despite an increase in the number of novel anti-cancer drugs, the persistence of drug resistance remains a major challenge in cancer research and drug development. Many of the models used in the early stages of research fail to capture cancer’s mechanisms of resistance to therapeutics, impeding progress in drug development and clinical trials. To overcome drug resistance in diseases such as melanoma, cancer researchers need advanced whole cell models that contain defined genetic drug resistance mechanisms to facilitate the development of next-generation therapeutics. In this webinar, an ATCC expert highlights how innovative drug-resistant isogenic and reporter-labeled cell models created by CRISPR genome-editing technology can facilitate the discovery of new types of therapeutics that surmount drug resistance.
Key Points
- Therapeutic resistance in cancer is multifactorial and heterogeneous
- Many of the models used in the early stages of research are incapable of capturing cancer’s mechanisms of resistance to therapeutics
- ATCC scientists created advanced cell models to create KRAS mutant A375 cell lines
- These cell lines were validated on the genomic, transcriptional, and functional levels
Presenter
Fang Tian, PhD
Director, Biological Content, ATCC
Dr. Fang Tian, Director of Biological Content for ATCC, has extensive experience in cell biology and molecular biology. She oversees human, animal cell lines and hybridomas, and product development in the Cell Biology General Collection at ATCC. Dr. Tian was a research fellow in Massachusetts General Hospital, Harvard Medical School. She conducted postdoctoral research at the Hillman Cancer Institute of UPMC.
